CD274 and non-small cell lung carcinoma: Preliminary results of the ENCORE-601 trial involving entinostat with pembrolizumab in checkpoint refractory non-small cell lung cancer (NSCLC) demonstrated clinical efficacy in multiple patients regardless of prior checkpoint treatment or PD-L1 status (28).